Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.34 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3380418 | 0.81 | HDAC3 (0.50) | TSHR | |
| SCHEMBL3380559 | 0.81 | MAPT (0.36) | RIPK1ALDH1A1CYP1A2CYP2D6TSHR | |
| SCHEMBL3382276 | 0.80 | MAPT (0.50) | TSHR | |
| SCHEMBL3382732 | 0.74 | AKR1B1 (0.39) | ALDH1A1CYP1A2TSHR | |
| SCHEMBL8585562 | 0.73 | NAALAD2 (0.40) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| SCHEMBL1716157 | 0.73 | CYSLTR2 (0.50) | RIPK1CYSLTR2CYSLTR1ALDH1A1CYP1A2 | |
| SCHEMBL8457132 | 0.73 | KEAP1 (0.41) | ALDH1A1HPGDANPEPFOLH1 | |
| SCHEMBL8024424 | 0.72 | TBXAS1 (0.53) | RIPK1CYSLTR2CYSLTR1ALDH1A1CYP1A2 | |
| SCHEMBL3825484 | 0.72 | GRM8 (0.49) | RIPK1ALDH1A1CYP1A2CYP2D6TSHR | |
| SCHEMBL1373545 | 0.72 | GRM3 (0.54) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5880112-A | PHOSPHINIC ACID DERIVATIVES; PROSTATE CANCER TREATMENT | GUILFORD PHARMACEUTICALS INC. (US) | 1999-03-09 | — | — | US | claimed |
| EP-1443954-B1 | TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES | SCRIPPS RESEARCH INST (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7399743-B2 | Targeted thrombosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1443954-A2 | TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES | Novartis Pharma GmbH (AT) | 2004-08-11 | — | — | EP | disclosed |
| US-20030194400-A1 | Targeted thrombosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-16 | — | — | US | disclosed |
| WO-2003035688-A2 | TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES | NOVARTIS PHARMA GMBH (AT) | 2003-05-01 | — | — | WO | disclosed |
| US-5880112-A | PHOSPHINIC ACID DERIVATIVES; PROSTATE CANCER TREATMENT | GUILFORD PHARMACEUTICALS INC. (US) | 1999-03-09 | — | — | US | disclosed |
| US-5804602-A | N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-09-08 | — | — | US | disclosed |
| US-5672592-A | HYDROLASE INHIBITORS, ANTITUMOR AND ANTICARCINOGENIC AGENTS, FOR PROSTATE CANCER | GUILFORD PHARMACEUTICALS INC. (US) | 1997-09-30 | — | — | US | disclosed |